Why the study?
Do platelet-inhibiting drugs prevent clinical thrombotic disease in patients with coronary heart disease?
Do platelet-inhibiting drugs prevent clinical thrombotic disease in patients with coronary heart disease?
The article discusses the rationale and methodological challenges of conducting clinical trials for platelet-inhibiting drugs in the prevention of coronary heart disease.
Answers are grounded in this paper and cite their sources.
Does not resolve platelet inhibitor efficacy in coronary prevention; leaves open key methodological questions for future trials.
Coronary Heart DiseaseIn coronary heart disease, there is evidence that platelets may be involved, both by their incorporation into occlusive thrombi and by embolization of aggregates into the microcirculation.3–5,38,39The conduct of clinical trials in coronary heart disease presents major difficulties, the most important of which relates to the large number of patients required to perform the study in a reasonable time, since the incidence of the end points, myocardial infarction and death, is low. If a primary prevention study were performed on randomly selected middle-aged subjects without evidence of overt coronary-artery disease, and myocardial . . .
No takes yet. Share an insight, caveat, or question.
Genton et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: